May 14, 2020 / 03:00PM GMT
Chi Meng Fong - BofA Merrill Lynch, Research Division - Research Analyst
Hi, Good morning. This is Chi Fong. I'm one of the associates from Jason Gerberry's midcap biotech and spec pharm team here at Bank of America. Today I'm pleased to be joined by Chris Anzalone, CEO of Arrowhead Pharmaceuticals. And Chris, thanks for taking the time to speak with us today. Pleased to have you here with us.
Maybe to start, maybe for those in case -- who may not be aware of the company, can you talk about -- a little about the company, what it does and where the company is at in terms of development stage and maybe some of the overall -- maybe like a broad view of the pipeline programs. Thank you.
Christopher R. Anzalone - Arrowhead Pharmaceuticals, Inc. - CEO, President & Director
Sure. Well, thanks very much, Chi, and thank you for inviting us today and enabling us to have investor meetings, and then of course this fireside chat. It's really a pleasure to be here.
So we are Arrowhead Pharmaceuticals. We're an RNAi company. I think that this is a really
Arrowhead Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers